论文部分内容阅读
单用或联合应用 VDS 治疗晚期恶性肿瘤22例。单用 VDS3mg/(m~2·周),静脉滴注,共4～6次。联合应用治疗淋巴瘤,以 VDS 取代 CHOP 方案中的 VCR;肺癌在CAP 方案中加 VDS;卵巢癌采用 PDD+CTX+VDS 并用 VCR 作对照。在可评价疗效的病例中,单用总有效率44.4%(4/9例);联合应用总有效率76.9%,治疗淋巴瘤(5/6例)、肺癌(3/5例)及卵巢癌(2/2例)有较好的效果。毒性可耐受,但骨髓抑制较重。结果提示VDS 有可能作为淋巴瘤第一线方案的组成药物;亦可与其他更有效的药物联合治疗肺癌及卵巢癌,值得前瞻性研究。
Single or combined VDS treatment of 22 cases of advanced malignant tumors. VDS3mg/(m~2·week) alone, IV infusion, total 4 to 6 times. In combination with lymphoma treatment, VDS was substituted for VCR in the CHOP protocol; lung cancer was treated with VDS in the CAP protocol; ovarian cancer was treated with PDD+CTX+VDS and VCR was used as a control. In efficacy-evaluable cases, the total effective rate was 44.4% (4/9); the total effective rate was 76.9%; the treatment of lymphoma (5/6 cases), lung cancer (3/5 cases), and ovarian cancer. (2/2 cases) have better results. Toxicity can be tolerated, but bone marrow suppression is heavier. The results suggest that VDS may be used as a component drug for lymphoma first-line regimens; it may also be used in combination with other more effective drugs for the treatment of lung and ovarian cancer, which is worthy of prospective studies.